Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
4Life Patents LLC manages a portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the current prosecution is split between different technical and administrative channels within the patent office.
HOFFMAN, SUSAN COE is the busiest examiner, currently overseeing 1 pending office action. Given that there are 2 distinct examiners and 2 pending office actions in total, the workload is evenly divided among the identified individuals. This 1 pending office action for HOFFMAN, SUSAN COE represents a portion of the total active prosecution for the company.
The involvement of 2 distinct art units suggests that the subject matter of the 2 pending office actions covers different technical areas within the Biotechnology & Pharmaceuticals technology area. This diversity requires the company to adapt to the specific preferences of 2 distinct examiners. The current data reflects a decentralized approach to patent acquisition, with no individual examiner handling the entirety of the portfolio's active workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOFFMAN, SUSAN COE | 1 | 54.2% | +25.7% |
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16380952 | PROBIOTIC COMPOSITIONS INCLUDING IMMUNE MODULATORS | HOFFMAN, SUSAN COE | 70d |
| 14698698 | COMBINED PROTEIN SUPPLEMENTS | REYNOLDS, FRED H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16380952 | PROBIOTIC COMPOSITIONS INCLUDING IMMUNE MODULATORS | HOFFMAN, SUSAN COE | 70d |
| 14698698 | COMBINED PROTEIN SUPPLEMENTS | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16380952 | PROBIOTIC COMPOSITIONS INCLUDING IMMUNE MODULATORS | HOFFMAN, SUSAN COE | 1655 | §102§103Other | Final Rejection | 70d | Pending | Apr 10, 2019 |
| 14698698 | COMBINED PROTEIN SUPPLEMENTS | REYNOLDS, FRED H | 1658 | §103§112 | Final Rejection | — | Pending | Apr 28, 2015 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial4Life Patents LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Susan Coe Hoffman has the most, with 1 of 4Life Patents LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
